Loading...
XSTOVIVE
Market cap13mUSD
Dec 23, Last price  
0.27SEK
1D
-2.67%
1Q
11.86%
Jan 2017
-95.24%
IPO
-98.24%
Name

Vivesto AB

Chart & Performance

D1W1MN
XSTO:VIVE chart
P/E
—
P/S
144.98
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.88%
Rev. gr., 5y
27.27%
Revenues
1m
-96.12%
11853,22222,387,00071,158,00079,357,00030,741,000106,000891,000060,0002,070,0006,373,000172,0003,169,0001,980,000201,843,000201,843,00026,192,0001,015,000
Net income
-367m
L+164.15%
2,505,381-7,306,969-9,757,000-5,067,000-7,105,000-17,054,000-65,960,000-65,670,000-72,381,000-105,112,000-117,497,000-141,539,000-160,243,000-118,007,000-171,020,000-10,533,000-10,533,000-138,945,000-367,030,000
CFO
-81m
L-44.69%
6,529,528-11,270,940-22,735,0009,00014,276,000-11,235,000-57,598,000-52,439,000-69,539,000-86,899,000-107,665,000-128,126,000-133,011,000-123,634,000-118,839,000-6,866,000-204,862,500-145,565,000-80,517,000
Earnings
Feb 20, 2025

Profile

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
URL
https://www.vivesto.com/
IPO date
Jan 01, 2005
Employees
19
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2022‑122021‑122020‑122020‑102020‑042019‑042018‑042017‑042016‑042015‑04
Income
Revenues
1,015
-96.12%
26,192
-87.02%
Cost of revenue
11,671
123,560
Unusual Expense (Income)
NOPBT
(10,656)
(97,368)
NOPBT Margin
Operating Taxes
10,311
6,223
Tax Rate
NOPAT
(20,967)
(103,591)
Net income
(367,030)
164.15%
(138,945)
1,219.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
150,652
BB yield
-70.38%
Debt
Debt current
2,987
5,287
Long-term debt
13,349
15,569
Deferred revenue
Other long-term liabilities
Net debt
6,568
12,643
Cash flow
Cash from operating activities
(80,517)
(145,565)
CAPEX
(277)
(34,349)
Cash from investing activities
(45,277)
118,651
Cash from financing activities
128,763
(5,809)
FCF
(11,764)
(92,418)
Balance
Cash
142,513
97,269
Long term investments
(132,745)
(89,056)
Excess cash
9,717
6,903
Stockholders' equity
(1,704,294)
(1,356,542)
Invested Capital
2,037,038
1,915,123
ROIC
ROCE
EV
Common stock shares outstanding
493,207
448,370
Price
0.43
-83.45%
2.62
-65.10%
Market cap
214,052
-81.80%
1,176,075
-60.72%
EV
220,620
1,188,718
EBITDA
245,499
(68,491)
EV/EBITDA
0.90
Interest
495
6,303
Interest/NOPBT